KORU Medical Systems (NASDAQ:KRMD) Releases Quarterly Earnings Results, Meets Expectations

KORU Medical Systems (NASDAQ:KRMD) posted its quarterly earnings data on Wednesday. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02), Zacks reports. The business had revenue of $11.76 million during the quarter, compared to the consensus estimate of $11.28 million. KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%.

Here are the key takeaways from KORU Medical Systems’ conference call:

• Q1 results beat expectations with $11.8M revenue (+22% YoY), adjusted EBITDA essentially break‑even (-$10k) and net loss improving 33% to $0.8M, while cash usage was minimal at $0.1M leaving $8.8M on the balance sheet.
• Management reiterated full‑year 2026 guidance of $47.5M–$50M revenue (15%–22% growth), 61%–63% gross margin, and positive adjusted EBITDA and cash flow, and retains access to a $10M debt facility.
• International expansion showed strong traction (international core +35%) driven by EU prefilled‑syringe conversions and distributor pump orders, supported by Freedom60 MDR clearance for prefilled syringe compatibility.
• The non‑IG pipeline advanced—now eight active non‑IG opportunities (>6M potential annual infusions), two pharma partners moved into phase III (including Apellis EMPAVELI in DGF), and a 510(k) was submitted for deferoxamine, while vancomycin was deprioritized.
• Q1 gross margin compressed to 61.5% (down 130 bps) due to production timing and tariff charges, although management says adjusted margins and cost initiatives keep full‑year margin guidance intact.

KORU Medical Systems Price Performance

Shares of KORU Medical Systems stock traded down $0.24 on Friday, hitting $4.20. 146,690 shares of the company’s stock traded hands, compared to its average volume of 120,097. The company has a fifty day moving average of $4.34 and a two-hundred day moving average of $4.85. KORU Medical Systems has a one year low of $2.63 and a one year high of $6.61. The company has a market capitalization of $192.91 million, a price-to-earnings ratio of -84.00 and a beta of 0.43.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. B. Riley Financial increased their price target on KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Wall Street Zen cut KORU Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Craig Hallum reissued a “buy” rating and set a $7.00 target price on shares of KORU Medical Systems in a research report on Tuesday, January 13th. Canaccord Genuity Group restated a “buy” rating and set a $6.00 price target on shares of KORU Medical Systems in a report on Friday, March 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Tuesday, April 21st. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, KORU Medical Systems currently has a consensus rating of “Moderate Buy” and an average target price of $7.25.

Hedge Funds Weigh In On KORU Medical Systems

Several institutional investors have recently added to or reduced their stakes in KRMD. BNP Paribas Financial Markets raised its stake in KORU Medical Systems by 52.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after buying an additional 3,478 shares during the period. Lazard Asset Management LLC bought a new stake in KORU Medical Systems during the 2nd quarter valued at $59,000. Acadian Asset Management LLC acquired a new position in KORU Medical Systems during the first quarter worth $63,000. Invesco Ltd. acquired a new position in KORU Medical Systems during the second quarter worth $80,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of KORU Medical Systems in the second quarter valued at $83,000. 58.60% of the stock is owned by institutional investors and hedge funds.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.